Virtus Investment Advisers LLC Lowers Stock Position in Pharvaris N.V. $PHVS

Virtus Investment Advisers LLC trimmed its stake in Pharvaris N.V. (NASDAQ:PHVS) by 36.8% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 5,457 shares of the company’s stock after selling 3,179 shares during the period. Virtus Investment Advisers LLC’s holdings in Pharvaris were worth $96,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in PHVS. Palumbo Wealth Management LLC increased its holdings in Pharvaris by 3.2% in the 2nd quarter. Palumbo Wealth Management LLC now owns 14,549 shares of the company’s stock valued at $256,000 after purchasing an additional 447 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after buying an additional 783 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after buying an additional 1,695 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new stake in shares of Pharvaris in the 2nd quarter valued at $57,000. Finally, Deutsche Bank AG lifted its stake in Pharvaris by 55.1% during the 1st quarter. Deutsche Bank AG now owns 28,174 shares of the company’s stock worth $442,000 after acquiring an additional 10,006 shares in the last quarter.

Analysts Set New Price Targets

PHVS has been the subject of several research reports. Bank of America raised Pharvaris from an “underperform” rating to a “neutral” rating and lifted their target price for the company from $16.00 to $27.00 in a research report on Thursday, October 9th. Morgan Stanley lifted their price objective on shares of Pharvaris from $34.00 to $37.00 and gave the company an “overweight” rating in a report on Friday, November 14th. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Pharvaris in a report on Thursday, November 13th. Zacks Research upgraded shares of Pharvaris from a “strong sell” rating to a “hold” rating in a research note on Monday, August 18th. Finally, Citigroup reiterated a “market outperform” rating on shares of Pharvaris in a research note on Wednesday, November 19th. Seven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $37.57.

Pharvaris Trading Up 2.0%

Pharvaris stock opened at $28.27 on Monday. The company has a fifty day simple moving average of $23.60 and a 200-day simple moving average of $21.29. The stock has a market cap of $1.48 billion, a P/E ratio of -8.81 and a beta of -2.78. Pharvaris N.V. has a 12-month low of $11.51 and a 12-month high of $28.48.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.08. As a group, sell-side analysts forecast that Pharvaris N.V. will post -2.71 earnings per share for the current fiscal year.

Pharvaris Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.